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Summary: We have developed a kinetic fixed-time approach for the quantitative determination of serum glucose by
use of the hexokinase/glucose-6-phosphate dehydrogenase method. To achieve a large measuring range, we have
apparently increased the Michaelis constant of glucose-6-phosphate dehydrogenase through addition of the com-
petitive inhibitor ATP. By this means, serum samples with glucose concentrations up to 55.5 mmol/1 could be ana-
lyzed without pre-dilution. The method has been adapted to the ENI GEMSAEC analyzer and to the LKB 2086 Mark
II analyzer. It yielded satisfactory results with regard to precision. A comparison of the kinetic procedure with the
manual end-point method showed good agreement. No interferences from hemoglobin, bilirubin, or lipemia have
been observed.
Kinetische Bestimmung von Glucose im Serum mit der Hexokinase/Glucose-6-phosphat-Dehydrogenase-Methode
Zusammenfassung: Wir haben für die quantitative Bestimmung der Serumglucose nach der Hexokinase/Glucose-6-
phosphat-Dehydrogenase-Methode ein kinetisches "fixed-time"-Verfahren entwickelt. Um für das Verfahren einen
großen Meßbereich zu erhalten, wurde die Michaelis-Konstante der Glucose-6-phosphat-Dehydrogenase durch Zugabe
des kompetitiven Inhibitors ATP scheinbar erhöht. Auf diese Weise konnten Serumproben mit einer Glucosekonzen-
tration bis 55,5 mmol/1 ohne Vorverdünnung bestimmt werden. Die Methode wurde auf die Analysenautomaten ENI
GEMSAEC und LKB 2086 Mark II adaptiert. Die Untersuchung der Präzision lieferte zufriedenstellende Ergebnisse.
Ein Vergleich der kinetischen Methode mit der manuellen Endwert-Methode zeigte gute Übereinstimmung. Störungen
durch Hämoglobin, Bilirubin oder Lipämie traten nicht auf.
Introduction The assay is commonly carried out as an end-point
procedure (1 ,2). To improve the convenience of the
Due to its specificity and its inserisitivity to interference,
 method for the autOmated clinical laboratory, we
the hexokinase/glucose-6-phosphate dehydrogenase
 studied the feasibuity of a kinetic fixed-time approach
method has found worldwide acceptance as a reference
 which allpws reduction of the reaction time and omission
method for the determination of glucose in body fluids
 of the technically elaborate determination of the initial
(1). It is based on the following reaction sequence in absorbance (3).
which the second step is responsible for the high specific
city of the assay (2). Because of the low Michaelis constant of glucose-6-
phosphate dehydrogenase with respect to glucose-6-
Hexokinase phosphate (4), the kinetic glucose assay using this en-
Z>-Glucose + ATP
 gc ·> />-Glucose-6-phosphate + ADP Zyme and hexokinase is not, at first sight, suited for the
determination of high glucose concentrations (3). Ho w-
Giucose-6-P ever, following the theory of Michaelis andMenten, this
the additi
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value of the enzyme (3,5). Therefore, we first looked
for a suitable compound which competitively inhibits
glucose-6-phosphate dehydrogenase with respect to
glucose-6-phosphate. The kinetic glucose assay was then
performed in the presence of this inhibitor, using an ENI
GEMSAEC analyzer and an LKB 2086 Mark II analyzer.
Materials and Methods
Apparatus
The automated methods were performed using an ENI GEMSAEC
centrifugal analyzer (Electro-Nucleonics, 368 Passaic Ave., Fair-
field, N.J. 07006) and a LKB 2086 Mark II kinetic analyzer
(LKB Clinicon AB, S-16126 Bromma, Sweden). For the LKB
2086 Mark II method, samples and reagents were dispensed with
an LKB 2075 diluter. Manual assays were done with a Model
1101 M spectrum line photometer which was connected with
a Model 6511 recorder (Eppendorf Ger tebau Netheler & Hinz
GmbH, D-2000 Hamburg 63).
Reagents
Hexokinase test kit "Gluco-quant", cat. No. 245178; ATP cat. No.
127 531; jS-D-glucose-6-phosphate, cat. No. 105 333; NADP, cat.
No. 128 040; glucose standards "Preciset Glucose", cat. No.
125 563, and glucose-6-phosphate dehydrogenase frprn Leucono-
stoc mesenteroides, cat. No. 165 883, were all from goehringer
Mannheim, P.O. Box 51, D-6800 Mannheim 31, Germany, D-
glucose and bilirubin were from E. Merck, D-6100 Darmstidt,
Germany. According to the manufacturer's instructions reagent
1 of the test kit was reconstituted to 200 ml with distilled water
giving a concentration of 70 mmol/1 phosphate buffer (pH 7.7),
1.3 mmol/1 NADP, 1.3 mmol/1 ATP and 4 mmol/1 MgSO4.
Reagent 2 contained > 100 kU/1 hexokinase and > 180 kU/1
glucose-6-phosphate dehydrogenase.
For the GEMSAEC method, a single reagent was prepared by
adding 2 ml of reagent 2 and 1.80 g (2.97 mmol) of ATP to
200 ml of reagent 1 solution. For the LKB 2086 Mark II method,
3.15 g (5.20 mmol) of ATP was added to 200 ml of reagent 1
solution. The starting reagent was obtained by mixing 20 ml of
this solution with 2 ml of reagent 2. For the inhibition studies,
an assay mixture was prepared by adding 20 U of glucose-6-
phosphate dehydrogenase and varying ATP concentrations to
200 ml of reagent 1 solution. The reagents were stable for at
least one day at 25 °C.
Samples
The sera used in the experiments were from patients. High
glucose concentrations were obtained by adding various amounts
of glucose to a human serum pool. Control sera were all from
Boehringer Mannheim.
Procedures
GEMSAEC
The adjustment of the GEMSAEC system was as follows:
Rotoloader: sample-switch, B; blank-switch, water; sample
volume, 5 μΐ; flush volume, 150 μΐ (physiological saline diluent);
reagent volume, 500 μΐ. The reagent was pipetted into well C of
the transfer disk.
Analyzer: reaction temperature, 25 °C; wavelength, 34Q nm;
filter range, 335-385 nm,
Control: reaction mode, rate; running mode, auto; initial
reading (IR), 25 s; reading interval (El), 10 s; number of readings
(NR),5.
The sample ring was loaded in the following sequence: position
1, distilled water; position 2, standard (5.55 mmol/1); positions
3-16, control sera and patient's samples. The calculation of the
results was performed with the computer program TC = 5 which
is designed for routine kinetic fixed-time analysis (Electro^
Nucleonics International LTD, Adriaan van Bergenstraat 202-
208,4811 SW Breda, Holland).
LKB 2086 Mark II
The LKB-system was set up as follows:
Analyzer: temperature, 25 °C; wavelength, 340 nm, light
setting, 0.7 A; reaction course, increase; dispensing volume,
100 μΐ; injection position, 2; delay, on; measuring range, 0.2;
cuvette, 10 mm, timer, 5 min.; feed-in-switch, timer.
Data Processor: program type, fixed time; delay, yes; time of
first measurement, Os; time of second measurement, 30 s;
regression, linear; number of standards, 3; concentration of
standards, 5.55 mmol/1; deviation for deleting standard samples,
10%.
10 μΐ of calibration standard or sample and 900 μΐ of reagent 1
solution were dispensed into the 10 mm disposables cuvettes.
Other procedures
The manual assays were carried out in 1 cm cuvettes at 25 °C
and at Hg 365 nm. For measuring the activity of glucose-6-
phosphate dehydrogenase in the presence of varying ATP con-
centrations, 2 ml of the assay mixture and 20 μΐ of glucose-
6-phosphate-solution were used. The reaction was started by
addition of glucose-6-phosphate. For determining the type of
inhibition, the initial rates were measured and their reciprocal
values plotted vs. the reciprocal substrate concentrations.
Results and Discussion
At present, in commercially available test kits for the
determination of glucose according to the hexokinase
end-point procedure, the glucose-o^phosphate dehydro-
genase from Leycpriostoc mesenteroides is commonly
used. This enzyme is known to be inhibited by pyridoxal-
phosphate (6), ATP and acyl-CoA derivatives (7). Stimula-
ted by the fact that ATP is already employed as low-
priced and stable competitive inhibitor for the kinetic
determination of serum triglycerides (8) we preferably
looked into the suitability of that substance for the
kinetic glucose assay.
To determine the type of inhibition of glucose^phos-
phate dehydrogenase by ATP, we first studied the
kinetics of this enzymatic reaction in the presence of
increasing amounts of ATP. The results of the experi-
ments are shown in figure 1, using a Lineweaver^Burk
plot (9). As indicated by the common point of inter?
section of the curves on the 1/v axis, ATP exerts a com-
petitive type of inhibition with respect to glucose-6-
phosphate.
This finding suggested to us that, for the kinetic glucose
assay, the Km-value of glucose-6-phosphate dehydro-
gen se could be increased by simply elevating the ATP
concentration usually employed for the end-point
method. An ATP concentration of about 17 nimol/l
in the reaction mixture was calculated to cause the
required shift of the Michaelis constant (3). Figure 2
demonstrates that under these conditions, after a short
lag phase, the overall reaction of the glucose assay
followed pse do-first-order kinetics with respect to
glucose concentration. This, however, is known to be
the basic requirement for a kinetic substrate determ-
ination by use of the fixed-time procedure (3):
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Fig. 3. Fixed-time absorbance change as a function of glucose
concentration, measured with the GEMSAEC.
Fig. 1. Inhibition of glucose-6-phosphate dehydrogenase by ATP.
to exist between the fixed-time absorbance changes and
the respective glucose concentrations. Furthermore, the
figure demonstrates that the sensitivity of the assay was
sufficiently high in the normal range of glucose. With the
LKB 2086 Mark II method, the measuring range was
found to extend up to 44.4 mmol/1 glucose.
Precision
Table 1 lists the within-run precision of the present
method. The data were obtained by simultaneous analysis
of aliquots of calibration standard, normal and supranor-
mal human sera. Day-to-day precision was studied for
six days by repeated analysis of the control serum Preci-
norm U (Boehringer Mannheim). Satisfactory results were
obtained with both methods; GEMSAEC: mean = 5.45
mmol/1, CV = 2.5 %; LKB 2086 Mark II: Mean = 5.38
mmol/1, CV = 3.4 %.
Tab. 1. Within-run precision of present method.
Fig. 2. Time course of reaction. A absorbance at tiine t, A«»
absoibance after completion of reaction. Samples:
glucose standards A,-—A 2.78 mmol/1, ·—· 5.55 mmol/1,
•—τ· 11.10 mmol/1, ο—ο 22.20 mmol/1. The response
curves were recorded at Hg 365 nm using the GEMSAEC
reagent.
Measuring range and sensitivity
We assayed dilutions of stock solution of high purity D^
glucose giving concentrations between 2.78 and 55.5
mmol/1. Figure 3 shows the results obtained with the
GEMSAEC method. A straight line relationship was found
Method
GEM-
SAEC
LKB
2086
Mark II
Sample
Standard
Serum
Serum
Serum
Serum
Standard
Serum
Serum
Serum
Serum
No.
14
14
14
14
14
20
20
20
20
20
Glucose
tests (mmol/1)
X
5.57
5.22
7.53
11.98
29.82
5.53
5.43
8.73
12.98
23.41
± s
0.04
0.05
0.06
0.08
0.21
0.05
0.05
0.09
0.15
0.32
CV(%)
0.72
0.96
0.80
0.67
0.70
0.90
0.92
1.03
1.16
1.37
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Accuracy
The correlation of the automated methods with the
manual hexokinase end-point method was tested on 59
native human sera.
The results obtained with the GEMSAEC method are
illustrated in figure 4. The calculated regression para-
meters indicate the good accuracy of the method.
Equally satisfactory results were obtained with the
LKB 2086 Mark II method: y = 0.981 χ + 0.578,
r = 0.997.
Tab. 2. Effect of added bilirubin or hemoglobin on the glucose
value of a human serum, as measured by the GEMSAEC
method.
Bilirubin added
(μπιρί/ΐ)
20
80
160
Hemoglobin added Glucose found*
(μιηρί/ΐ) (fnmol/1)
10.32
10.30
10.42
10.51
15 10.36
60 10.52
150 10.48
!
 mean values of triplicate determination
60
ε
l·0
20
20 40
Glucose (manual method) [mmol/ll
60
Fig. 4. Comparison of present GEMSAEC method (y) with
manual hexokinase method (x) for glucose in native
human sera, n = 59, y = 0.987x + 0.26, r = 0.998.
Similar correlations between the kinetic methods and the
endpoint method were observed using plasma samples
(EDTA, heparin, citrate).
Interferences
As illustrated in table 2, colored blood components did
not interfere with the kinetic method. The samples used
in this experiment were taken from a human serum pool
and different amounts of bilirubin or hemoglobin were
added. Also no interference was observed from lipemia.
Conclusions
The present study shows that the reference method for
the determination of glucose, the hexokinase/glucose-
6-phosphate dehydrogenase method, can be carried out
kinetically over a wide range of glucose concentration if
appropriate assay conditions are used. The kinetic
approach, however, is especially suited for automated
instruments. It allows a short reaction time. Neither
analysis of reagent or sample blanks nor determination
of initial absorbances is needed.
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